Therapeutic Efficacy in Women With Stress Urinary Incontinence
NCT ID: NCT05677295
Last Updated: 2023-05-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
PHASE3
90 participants
INTERVENTIONAL
2023-04-18
2024-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical and Urodynamic Effects of Minimally Laser (IncontiLaseTM) Procedure for Female Stress Urinary Incontinence
NCT02130375
Efficacy and Safety of Duloxetine, Placebo and Pelvic Floor Muscle Training in Subjects With Stress Urinary Incontinence
NCT00190606
Dynamic Neuromuscular Stabilization vs Pelvic Floor Muscle Training in Women With Stress Urinary Incontinence
NCT07075900
Outpatient and Home Pelvic Floor Training for Stress Urinary Incontinence
NCT03058042
Comparison Between Positive and Negative sUPP
NCT06783699
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Patients and Methods: We will perform a prospective randomized controlled study to recruit 90 female SUI patients at the Obstetrics \& Gynecology outpatient clinic of Far Eastern Memorial Hospital. All SUI female patients will be asked to complete ICIQ-UI, USS, OABSS, and bladder diary before and after 4 weeks' duloxetine versus imipramine treatment.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Duloxetine
duloxetine
Duloxetine 30 mg per day
Imipramine
Imipramine
Imipramine 25 mg per day
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
duloxetine
Duloxetine 30 mg per day
Imipramine
Imipramine 25 mg per day
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who are currently not considered for surgical treatment.
* Patients who have undergone regular Kegel exercises but have poor results.
Exclusion Criteria
* Those who are taking or plan to take monoamine oxidase inhibitor (MAOI) inhibitors.
* Patients with acute myocardial infarction.
* Those who are allergic to duloxetine, imipramine and dibenzazepine tricyclic antidepressants.
* Patients with uncontrolled narrow-angle glaucoma.
* Pregnant women.
* Those who are contraindicated to duloxetine or imipramine.
* Patients with suicidal ideation and behavior.
25 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Far Eastern Memorial Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sheng-Mou Hsiao
Chief and Professor, Department of Obstetrics and Gynecology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Obstetrics and Gynecology, Far Eastern Memorial Hospital
Banqiao District, New Taipei, Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
111220-F
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.